Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rivastigmine
Drug ID BADD_D01955
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status approved; investigational
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D03822
MeSH ID D000068836
PubChem ID 77991
TTD Drug ID D0WY5Q
NDC Product Code 16714-117; 70710-1198; 72855-101; 0781-7304; 65372-1153; 82245-0107; 51956-0001; 51956-0002; 51991-898; 65162-826; 72855-102; 49706-1825; 0078-0503; 63629-2065; 65162-749; 65162-825; 0378-9072; 0781-7309; 12651-118; 64552-4021; 65015-819; 0078-0501; 63629-8846; 0378-9071; 70710-1196; 16714-115; 63629-2066; 50379-0014; 65862-982; 72855-100; 51956-0003; 51991-897; 51991-899; 0781-7313; 63629-2064; 0378-9070; 0078-0502; 16714-116; 63629-8807; 70710-1197
UNII PKI06M3IW0
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C14H22N2O2
CAS Registry Number 123441-03-2
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.0040.002710%Not Available
Lung disorder22.02.07.0010.000813%Not Available
Malaise08.01.01.0030.011815%
Mania19.16.02.0020.000813%
Memory impairment19.20.01.003; 17.03.02.0030.007913%
Mental impairment19.21.02.003; 17.03.03.0020.002385%Not Available
Miosis06.05.03.003; 17.02.11.0020.001355%Not Available
Mitral valve incompetence02.07.01.002--Not Available
Mood altered19.04.02.0070.001734%Not Available
Movement disorder17.01.02.0100.001897%Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.002981%Not Available
Muscle twitching15.05.03.0050.000542%Not Available
Myocardial infarction02.02.02.007; 24.04.04.0090.002981%
Myoclonus17.02.05.0080.001084%Not Available
Nausea07.01.07.0010.017939%
Neoplasm16.16.02.001--Not Available
Neoplasm malignant16.16.01.001--Not Available
Nervousness19.06.02.0030.000542%Not Available
Neutrophilia01.02.01.0050.000813%Not Available
Nightmare19.02.03.0030.001734%Not Available
Nocturia20.02.03.0010.001084%Not Available
Nystagmus17.02.02.006; 06.05.02.0060.000813%
Oesophagitis07.08.05.0010.000813%
Oliguria20.01.03.0040.000813%Not Available
On and off phenomenon17.01.05.0040.002981%Not Available
Orthopnoea02.11.05.010; 22.02.01.0200.000542%Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.0200.001355%Not Available
Pallor24.03.04.001; 23.03.03.031; 08.01.03.032--Not Available
Pancreatitis07.18.01.0010.001084%
Pancreatitis acute07.18.01.0020.000813%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene